CEL-SCI News

VIENNA, Va. -- -- The following letter was provided to shareholders by CEL-SCI Corporation for today's annual shareholder meeting: Last year, 2011, was an exciting year for us because we were finally able to start our Phase III clinical trial for our investigational cancer drug Multikine *. This trial is the largest head and neck cancer study ever ... (more)

Financial and Strategic SWOT Analysis Review Summary CEL-SCI Corporation is a biotechnology company involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases.

SCI reported that net loss available to common shareholders for the quarter ended March 31, 2012 was $ versus $ during the same quarter ended March 31, 2011.

Despite the fact that shares have been quietly setting higher lows since the start of the year, when one does the math Cel-Sci still looks undervalued.